AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 985 participants.

Also called NCT07400107

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 985 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07400107
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Brazil, Bulgaria, Croatia, Germany, Hungary, India, Mexico, Poland, Portugal, Romania, Thailand, Türkiye (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07400107. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-20 (actual); primary completion 2028-12-19 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Acronym
AMAZE 8
Condition
Obesity
Condition
Overweight
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
NNC0487-0111
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo (matched to NNC0487-0111)
Intervention (Drug)
Placebo (matched to semaglutide)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07400107
Content hash
aaa731bbf5e12566921af013e0b6159badc008563e18b0a663981b0ad814ffe0